IMEIK(300896) Guoyuan Securities·2024-03-20 16:00Investment Rating - The report maintains a "Buy" rating for the company, expecting the stock price to outperform the Shanghai Composite Index by more than 20% in the next six months [6][14]. Core Insights - The company achieved a revenue of 2.869 billion yuan in 2023, representing a year-on-year growth of 47.99%. The net profit attributable to shareholders was 1.858 billion yuan, also up by 47.08% year-on-year [3][10]. - The gross margin for 2023 was 95.09%, with a slight increase of 0.25 percentage points year-on-year, while the net margin was 64.77%, down by 0.61 percentage points [3][10]. - The company has a robust product pipeline, including five drugs and biological products, and three medical devices currently under development [5]. Financial Performance - In 2023, the company reported a net profit of 1.858 billion yuan, a 47.08% increase from the previous year, with a non-recurring net profit of 1.831 billion yuan, up 52.95% [3][10]. - The company’s revenue for 2024 is projected to reach 3.975 billion yuan, with an expected year-on-year growth of 38.55% [10]. - The earnings per share (EPS) forecast for 2024-2026 is 11.63 yuan, 15.14 yuan, and 19.10 yuan, respectively, with corresponding price-to-earnings (P/E) ratios of 30x, 23x, and 18x [6][10]. Product and Market Development - The company has expanded its sales and marketing team to over 400 personnel, covering approximately 7,000 medical beauty institutions in China, an increase of about 2,000 from the previous year [3]. - The injection product segment showed strong growth, with solution-type injections generating 1.671 billion yuan in revenue, a 29.22% increase year-on-year, and gel-type injections achieving 1.158 billion yuan, up 81.43% [4]. - The company has signed a distribution agreement with Jeisys from South Korea to introduce two non-invasive skin rejuvenation devices to the domestic market, aiming to create a comprehensive solution for beauty treatments [4].